Evidence map›Paper›PMID 17357079›Full record

ArticleAmerican journal of human genetics2007

Assessing the functional characteristics of synonymous and nonsynonymous mutation candidates by use of large DNA constructs.

A M Eeds, D Mortlock, R Wade-Martins, M L Summar

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in American journal of human genetics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. CPS1: Looking at an ancient enzyme in a modern light.Molecular genetics and metabolism · 2020
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

A M EedsProgram in Translational Genetics, Center for Human Genetic Research, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
D Mortlock
R Wade-Martins
M L Summar
Center for Human Genetics · USCentre for Human Genetics · GB

Funding

Training (Career Development) ComponentU54HD061221 · NICHD · CHILDREN'S RESEARCH INSTITUTE · PI AH MEW, NICHOLAS, GROPMAN, ANDREA LYNNE · 2009 to 2023
$20.8M
RARE DISEASES CRC: UREA CYCLE DISORDERSU54RR019453 · NCRR · CHILDREN'S RESEARCH INSTITUTE · PI BATSHAW, MARK L. · 2003 to 2008
$7.0M
Gdf6 gene expression and evolution in vertebratesR01HD047880 · NICHD · VANDERBILT UNIVERSITY · PI MORTLOCK, DOUGLAS P · 2005 to 2009
$1.8M
Genetics Training Program: Implications of VariationT32GM062758 · NIGMS · VANDERBILT UNIVERSITY · PI PHILLIPS III, JOHN ATLAS · 2001 to 2005
$946k
NCRR NIH HHS RR19453-01NCRR NIH HHS U54 RR019453NICHD NIH HHS 1R01HD47880-01NICHD NIH HHS R01 HD047880NICHD NIH HHS U54 HD061221NIGMS NIH HHS 1T32GM062758NIGMS NIH HHS T32 GM062758Wellcome Trust
6 · The paper itself

Abstract

As we identify more and more genetic changes, either through mutation studies or population screens, we need powerful tools to study their potential molecular effects. With these tools, we can begin to understand the contributions of genetic variations to the wide range of human phenotypes. We used our catalogue of molecular changes in patients with carbamyl phosphate synthetase I (CPSI) deficiency to develop such a system for use in eukaryotic cells. We developed the tools and methods for rapidly modifying bacterial artificial chromosomes (BACs) for eukaryotic episomal replication, marker expression, and selection and then applied this protocol to a BAC containing the entire CPSI gene. Although this CPSI BAC construct was suitable for studying nonsynonymous mutations, potential splicing defects, and promoter variations, our focus was on studying potential splicing and RNA-processing defects to validate this system. In this article, we describe the construction of this system and subsequently examine the mechanism of four putative splicing mutations in patients deficient in CPSI. Using this model, we also demonstrate the reversible role of nonsense-mediated decay in all four mutations, using small interfering RNA knockdown of hUPF2. Furthermore, we were able to locate cryptic splicing sites for the two intronic mutations. This BAC-based system permits expression studies in the absence of patient RNA or tissues with relevant gene expression and provides experimental flexibility not available in genomic DNA or plasmid constructs. Our splicing and RNA degradation data demonstrate the advantages of using whole-gene constructs to study the effects of sequence variation on gene expression and function.

Indexed as

Gene ExpressionGenetic VariationPhenotypeAlternative SplicingBlotting, NorthernBlotting, WesternCarbamoyl-Phosphate Synthase (Ammonia)Chromosomes, Artificial, BacterialDNA Mutational AnalysisDNA PrimersGenetic VectorsHumansReverse Transcriptase Polymerase Chain ReactionRNA InterferenceTransfectionCarbamoyl-Phosphate Synthase (Ammonia)DNA Primers

Identifiers

PMID17357079
PMCPMC1852709
OpenAlexW2009316805

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.